Astellas VP-Business Development Masaki Doi: An Interview With "The Pink Sheet" DAILY (Part 2 0f 2)
This article was originally published in PharmAsia News
Executive Summary
"The Pink Sheet" DAILY visited recently with Astellas Pharma VP-Business Development Masaki Doi at the company's headquarters in Tokyo to talk about the Japanese pharma's global licensing strategy and the changing paradigm of Japanese deal flow. This is the second of a two-part interview. (Part 1 was printed yesterday in PharmAsia News).
You may also be interested in...
Pfizer, Astellas Execs Talk Deals At BIO Asia
TOKYO - Although the economic slump may seem like an opportune time for more mergers and acquisitions with big pharmas taking over biotechs, there are challenges to such an approach, pharma executives told attendees of the annual BIO Asia partnering conference Jan. 19
Pfizer, Astellas Execs Talk Deals At BIO Asia
TOKYO - Although the economic slump may seem like an opportune time for more mergers and acquisitions with big pharmas taking over biotechs, there are challenges to such an approach, pharma executives told attendees of the annual BIO Asia partnering conference Jan. 19
Mitsubishi, Tanabe Merge To Accelerate International Business Development
Consolidated company will be the fifth largest Japanese drug maker.